Meeting
2023 ASCO Annual Meeting
Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.
Authors
Melody Chang
American Oncology Network, Fort Myers, FL
Melody Chang , Jenny Li , Brooke Peters , Bradley Winegar , Robert Carr , Camilo Rodriguez , Ashley Kohler-Gerber , Darell Connor , Taqyra Freeman , Kyle Brown
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6516)
DOI
10.1200/JCO.2023.41.16_suppl.6516
Abstract #
6516
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Medicare reimbursement trends of biological reference agents and their biosimilars.
First Author: John Albaugh
Poster
2021 ASCO Quality Care Symposium
Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice.
First Author: Amit Sanyal
Poster
2023 ASCO Annual Meeting
System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.
First Author: Suwicha Limvorasak
Poster
2022 ASCO Quality Care Symposium
Estimating prevalence and financial impact of “bagging” oncology drugs: Evidence from privately-insured patients with cancer.
First Author: Ya-Chen Tina Shih